Technology
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Markers released top-line results today after previously reporting the trial succeeded.
Publication and source
PublicationSanalda Haber
SourceArs Technica
Published
CategoryTechnology
Summary from the source publisher’s news feed.